期刊
CURRENT OPINION IN IMMUNOLOGY
卷 40, 期 -, 页码 14-23出版社
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2016.02.008
关键词
-
类别
The clinical success of Adcetris (R) (brentuximab vedotin) and Kadcyla (R) (ado-trastuzumab emtansine) has sparked clinical development of novel ADCs. These powerful anti-cancer agents are designed to allow specific targeting of highly potent cytotoxic agents to tumor cells while sparing healthy tissues. Despite the use of tumor-specific antibodies, the emerging clinical data with ADCs indicates that adverse effects frequently occur before ADCs have reached their optimal therapeutic dose, resulting in a relatively narrow therapeutic window. This review summarizes the therapeutic window of ADCs currently in clinical development, along with some strategies that may help to widen the window.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据